Quach H; Lasica M; Routledge D; Kalff A; Lim A; Low M; Estell JA; Sidiqi MH; Campbell P; Eek RW; Lai HC; McCaughan GJ; D'Rozario J; Browlett P; Rajagopal R; Heenan J; Murphy NE; Renwick W; Huan G; Mollee P, 2021, 'A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.', in
JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,
http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS8055